Epilepsy – Current Treatment – Current Treatment: Physician Insights – Lennox-Gastaut Syndrome (US)
Lennox-Gastaut syndrome (LGS) is a severe pediatric-onset epilepsy syndrome characterized by developmental delays or regression, multiple seizure types, and electroencephalographic abnormalities. Eight antiepileptic drugs (AEDs), including Epidiolex, Fintepla, rufinamide, and clobazam, are approved for the adjunctive treatment of LGS, while others, such as levetiracetam, are often used off-label. Despite these options, full seizure control remains elusive for most patients, even with combination treatment. Neurologists must carefully weigh many factors when selecting an AED, often tailoring treatment through dose adjustments, additions, or switches between therapies to optimize seizure management in this vulnerable population. This report explores the factors influencing prescribers’ decision-making in managing LGS, examines their views on current treatment options, analyzes prescribing patterns, and highlights critical areas where unmet needs persist.
Questions answered
- What attributes drive the current prescribing patterns, recent anticipated changes in drug choice, and overall decision-making in LGS?
- Which therapies are dominant in the first, second, and third lines? What are the drivers and obstacles to using key brands, and what are the reasons for their discontinuation?
- What percentage of LGS patients are treated with monotherapy vs. combination therapy? What are the most used combinations?
- How has the availability of Epidiolex and Fintepla changed the prescribing of first- and second-generation therapies?
Markets covered: United States
Primary research: Survey of 105 U.S. neurologists, pediatric neurologists, and epileptologists
Key drugs covered: Epidiolex, clobazam, clonazepam, felbamate, Fintepla, lamotrigine, levetiracetam, rufinamide, topiramate, and valproate
Key analyses
- Factors influencing disease management and treatment decisions
- Drivers and constraints of treatment selection
- Physician-reported treatment practices and brand-level patient shares
Product description
Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:
- Understand the treatment landscape for a disease and how physicians make prescribing decisions.
- Evaluate the drivers and obstacles that influence treatment selection.
- Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
- Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.
